medigraphic.com
Revista Médica Sinergia

2020, Number 07

<< Back Next >>

Revista Médica Sinergia 2020; 5 (07)

Survival in patients with breast cancer according to their immunohistochemistry experience of the National Oncological Institute - Society for the Fight Against Cancer, Guayaquil, Ecuador

Ulloa OP, Ronquillo TS, Sánchez PK

Language: Spanish
References: 24
Page: 1-10
PDF size: 143.20 Kb.


ABSTRACT

Introduction: Breast cancer is the most common oncological pathology in the female population worldwide, it has been determined that its prognosis is linked to the diagnostic tumor stage, histological type and systemic treatment that is applied according to the molecular subtype. The objective of this study is to identify the association of the expression of hormonal receptors, HER2/neu and Ki67 with the survival of patients with breast cancer. Methods: A descriptive, retrospective study was carried out at the National Oncology Institute Dr. Juan Tanca Marengo in 284 patients diagnosed with breast cancer from January 2006 to December 2013. Age, histological diagnosis, clinical stage, molecular subtypes and survival variables were analyzed. Results: The average age was between 40 and 65 years, the most frequent histopathological diagnosis was infiltrating ductal carcinoma in 236 patients, the percentage of Ki67 was higher than 14% in 60% of those killed, the most frequent molecular subtype luminal B HER2 was positive with 95 cases and higher mortality in negative triples with 12.76%. Conclusion: Ki67 is a useful marker to assess the prognosis of the patient, the molecular classification of the tumor will allow directing the specific treatment and thereby obtaining the clinical re-staging of the patient.


REFERENCES

  1. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer, 127(12), 2893-2917. https://doi.org/10.1002/ijc.25516

  2. Cáncer en Guayaquil - Registro de Tumores 2011 - 2017 Autor: Sociedad de Lucha Contra el Cáncer Sede Nacional Instituto Oncológico Nacional - Dr. Juan Tanca Marengo Consejo Editorial: Dr. Juan Tanca Campozano Editor: Dr. Carlos Arreaga Salazar.

  3. Morrow, M., Strom, E. A., Bassett, L. W., Dershaw, D. D., Fowble, B., Harris, J. R.& Winchester, D. P. (2002). Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA: A Cancer Journal for Clinicians, 52(5), 256-276. https://doi.org/10.3322/canjclin.52.5.256

  4. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast.2008;17(4):323---34. https://doi.org/10.1016/j.breast.2008.02.002

  5. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067–9072. https://doi.org/10.1200/JCO.2004.01.0454

  6. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–820. https://doi.org/10.1056/NEJMoa053028

  7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–1672. https://doi.org/10.1056/NEJMoa052306

  8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–1684. https://doi.org/10.1056/NEJMoa052122

  9. Patani N, Martin LA, Dowsett M. Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer. 2013;133(1):1---13. https://doi.org/10.1002/ijc.27997

  10. Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-depen- dence of hazard ratios for prognostic factors inprimary breast can- cer. Breast Cancer Res Treat 1998;52:227–237. https://doi.org/10.1023/A:1006133418245

  11. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;365:1687–1717. https://doi.org/10.1016/S0140- 6736(05)66544-0

  12. Dowsett M, Allred C, Knox J, et al. Relationship between quanti- tative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex,Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:1059–1065. https://doi.org/10.1200/JCO.2007.12.9437

  13. Viale G, Regan MM, Maiorano E, et al. Prognostic and predic- tive value of centrally reviewed expression of estrogen and pro- gesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvanttherapy for postmenopausal early breast can- cer: BIG 1-98. J Clin Oncol 2007;25:3846–3852. https://doi.org/10.1200/JCO.2007.11.9453

  14. Viale G, Regan MM, Maiorano E, et al. Chemoendocrine com- pared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of es- trogen and progesterone receptors—International Breast Cancer Study Group. J Clin Oncol 2008;26:1404–1410. https://doi.org/10.1200/JCO.2007.10.6393

  15. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe- Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65. https://doi.org/10.1186/bcr2124

  16. De Azambuja E, Cardoso F, de Castro Jr G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96(10):1504---13. https://doi.org/10.1038/sj.bjc.6603756

  17. Sahin A, Ro J, Ro JY, Blick MB, el-Naggar AK, Ordonez NG, et al. Ki-67 immunostaining in node-negative stage I/II breast carcinoma Significant correlation with prognosis. Cancer.1991;68(3):549---57. https://doi.org/10.1002/1097-0142(19910801)68:3<549::AIDCNCR2820680318> 3.0.CO;2-J

  18. Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosumi M, Masuda S, et al. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Cancer Sci. 2013;104(11):1539---43. https://doi.org/10.1111/cas.12245

  19. Park S, Koo JS., Kim MS, Park HS, Lee JS, Lee JS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 2012; 21(1): 50–7. https://doi.org/10.1016/j.breast.2011.07.008

  20. JA VAN, CJH HAGE, VELDE JPJULIEN, Tubiana-Hulin M, Vandervelden C. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. Impact of age, tumor characteristics, and treatment on local control and disease outcome in early stage breast cancer. 2001;: p. 33. https://doi.org/10.1200/JCO.2001.19.22.4224

  21. Von Minckwitz G, Untch M, Blohmer J, Costa S, Eidtmann H, Fasching P, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. Journal of Clinical Oncology 2012; 30(15):1796-1804. https://doi.org/10.1200/JCO.2011.38.8595

  22. Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G,et al. Prevalence, morphologic features and proliferation indices of breastcarcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009;2:444-55.

  23. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep 1;24(9):2206–23. https://doi.org/10.1093/annonc/mdt303

  24. Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance). Journal of Clinical Oncology. 2017; 35: p. 1061. https://doi.org/10.1200/JCO.2016.69.4406




2020     |     www.medigraphic.com